Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI)

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Osteogenesis Imperfecta Foundation
Information provided by (Responsible Party):
Eric Orwoll, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT00131469
First received: August 16, 2005
Last updated: October 30, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2011
  Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
No publications provided by Oregon Health and Science University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):